OCV 101

Drug Profile

OCV 101

Alternative Names: OTS-11101

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Otsuka Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Jun 2015 Phase-II development for Pancreatic cancer is ongoing in Japan
  • 09 Jan 2015 Otsuka Pharmaceutical announces termination of its license agreement with OncoTherapy Science for OCV 101
  • 30 Sep 2014 OCV 101 is still in phase II development for Pancreatic cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top